RANDOMIZED CLINICAL-TRIAL OF 2 TREATMENT REGIMENS OF NATURAL SURFACTANT PREPARATIONS IN NEONATAL RESPIRATORY-DISTRESS-SYNDROME

被引:96
|
作者
SPEER, CP
GEFELLER, O
GRONECK, P
LAUFKOTTER, E
ROLL, C
HANSSLER, L
HARMS, K
HERTING, E
BOENISCH, H
WINDELER, J
ROBERTSON, B
机构
[1] UNIV GOTTINGEN, DEPT PAEDIAT, GOTTINGEN, GERMANY
[2] STADT KRANKENHAUS COLOGNE, DEPT MED STAT, COLOGNE, GERMANY
[3] STADT KRANKENHAUS COLOGNE, DEPT PAEDIAT, COLOGNE, GERMANY
[4] RUHR UNIV BOCHUM, DEPT PAEDIAT, BOCHUM, GERMANY
[5] UNIV ESSEN GESAMTHSCH, DEPT PAEDIAT, ESSEN, GERMANY
[6] STADT KRANKENHAUS BRAUNSCHWEIG, BRAUNSCHWEIG, GERMANY
[7] RUHR UNIV BOCHUM, DEPT MED INFORMAT & BIOMATH, BOCHUM, GERMANY
[8] KAROLINSKA INST, KAROLINSKA HOSP, RES UNIT EXPTL PERINATAL PATHOL, S-10401 STOCKHOLM, SWEDEN
关键词
SURFACTANT TREATMENT; RESPIRATORY DISTRESS SYNDROME; CUROSURF; SURVANTA;
D O I
10.1136/fn.72.1.F8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aims-To compare treatment regimens of two widely used natural surfactant preparations Curosurf and Survanta in respiratory distress syndrome (RDS). Methods-The effects of the two treatment regimens on gas exchange, ventilatory requirements, and 28 day outcome in infants with RDS were compared. Seventy fire preterm infants (birth weight 700-1500 g) with RDS requiring artificial ventilation with an FIO2 of greater than or equal to 0.4, were randomly selected at 1-24 hours of age. One group received an initial dose of Curosurf (200 mg/kg); the other group Survanta (100 mg/kg). Patients who remained dependent on artificial ventilation with an FIO2 of greater than or equal to 0.3 received up to two additional doses of Curosurf (each of 100 mg/kg) after 12 and 24 hours or up to three additional doses of Survanta (each of 100 mg/kg) between six and 48 hours after the initial dose. Results-There was a rapid improvement in oxygenation and ventilatory requirements were reduced in both groups. However, infants treated with Curosurf had a higher arterial:alveolar oxygen tension ratio and required a lower peak inspiratory pressure and mean airway pressure at several time points within 24 hours of randomisation (p<0.05-0.001). The incidences of pneumothorax in the Curosurf and Survanta groups were 6% and 12.5%, respectively; the corresponding figures for grades 3-4 intracerebral haemorrhage were 3% and 12.5%, respectively. Mortality was 3% in the Curosurf group and 12.5% in the Survanta group. However, these differences did not reach significance. Conclusion-The Curosurf treatment regimen resulted in a more rapid improvement in oxygenation than Survanta and reduced ventilatory requirements up to 24 hours aft er start of treatment. This was associated with a trend towards reduced incidence of serious pulmonary and nonpulmonary complications.
引用
收藏
页码:F8 / F13
页数:6
相关论文
共 50 条
  • [21] CONTROLLED RANDOMIZED TRIAL OF EARLY TREATMENT OF RESPIRATORY-DISTRESS SYNDROME WITH SURFACTANT
    JUNG, A
    MOLTENI, R
    CHAN, G
    WARD, R
    CLINICAL RESEARCH, 1990, 38 (01): : A203 - A203
  • [22] A MULTICENTER RANDOMIZED TRIAL COMPARING 2 SURFACTANTS FOR THE TREATMENT OF NEONATAL RESPIRATORY-DISTRESS SYNDROME
    HORBAR, JD
    WRIGHT, LL
    SOLL, RF
    WRIGHT, EC
    FANAROFF, AA
    KORONES, SB
    SHANKARAN, S
    OH, W
    FLETCHER, BD
    BAUER, CR
    TYSON, JE
    LEMONS, JA
    DONOVAN, EF
    STOLL, BJ
    STEVENSON, DD
    PAPILE, LA
    PHILIPS, J
    POLAND, RL
    TSANG, RC
    LITTLE, G
    BAIN, RP
    FOLEY, KA
    BANDSTRA, E
    MALLOY, M
    KENNEDY, K
    OSTREA, E
    EHRENKRAN, R
    HACK, M
    EDWARDS, W
    BRUMLEY, GW
    YOUNES, N
    DENNE, SC
    YAFFE, SJ
    BADA, H
    LUCEY, JF
    STONESTREET, B
    GROSS, I
    JOURNAL OF PEDIATRICS, 1993, 123 (05): : 757 - 766
  • [23] A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome
    Malloy, CA
    Nicoski, P
    Muraskas, JK
    ACTA PAEDIATRICA, 2005, 94 (06) : 779 - 784
  • [24] EARLY TREATMENT OF RESPIRATORY-DISTRESS SYNDROME WITH BOVINE SURFACTANT IN VERY PRETERM INFANTS - A MULTICENTER CONTROLLED CLINICAL-TRIAL
    GORTNER, L
    BARTMANN, P
    POHLANDT, F
    BERNSAU, U
    PORZ, F
    HELLWEGE, HH
    SEITZ, RC
    HIERONIMI, G
    BREMER, C
    JORCH, G
    HENTSCHEL, R
    REITER, HL
    WOLF, H
    BALL, F
    PEDIATRIC PULMONOLOGY, 1992, 14 (01) : 4 - 9
  • [25] Surfactant for respiratory distress syndrome: are there important clinical differences among preparations?
    Sinha, Sunil
    Moya, Fernando
    Donn, Steven M.
    CURRENT OPINION IN PEDIATRICS, 2007, 19 (02) : 150 - 154
  • [26] RESPIRATORY-DISTRESS-SYNDROME IN NEW-ZEALAND - EVIDENCE FROM THE OSIRIS TRIAL OF EXOGENOUS SURFACTANT (EXOSURF)
    WACH, R
    DARLOW, B
    BOURCHIER, D
    BROADBENT, R
    KNIGHT, D
    SELBY, R
    NEW ZEALAND MEDICAL JOURNAL, 1994, 107 (980) : 234 - 237
  • [27] Surfactant treatment for neonatal respiratory disorders other than respiratory distress syndrome
    Alkan, Senem
    Ozer, Esra Arun
    Ilhan, Ozkan
    Sutcuoglu, Sumer
    Tatli, Mansur
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2015, 28 (02): : 131 - 133
  • [28] SURFACTANT REPLACEMENT THERAPY IN NEONATAL RESPIRATORY-DISTRESS SYNDROME - A MULTI-CENTRE, RANDOMIZED CLINICAL-TRIAL - COMPARISON OF HIGH-DOSE VERSUS LOW-DOSE OF SURFACTANT TA
    KONISHI, M
    FUJIWARA, T
    NAITO, T
    TAKEUCHI, Y
    OGAWA, Y
    INUKAI, K
    FUJIMURA, M
    NAKAMURA, H
    HASHIMOTO, T
    EUROPEAN JOURNAL OF PEDIATRICS, 1988, 147 (01) : 20 - 25
  • [29] Comparison of efficacy and safety of two available natural surfactants in Iran, Curosurf and Survanta in treatment of neonatal respiratory distress syndrome: A randomized clinical trial
    Najafian, Bita
    Karimi-Sari, Hamidreza
    Khosravi, Mohammad Hossein
    Nikjoo, Niloofar
    Amin, Sobhan
    Shohrati, Majid
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2016, 3 : 55 - 59
  • [30] MULTICENTER RANDOMIZED TRIAL COMPARING HIGH AND LOW-DOSE SURFACTANT REGIMENS FOR THE TREATMENT OF RESPIRATORY-DISTRESS SYNDROME (THE CUROSURF-4 TRIAL)
    HALLIDAY, HL
    TARNOWMORDI, WO
    CORCORAN, JD
    PATTERSON, CC
    ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 1993, 69 (03): : 276 - 280